FrancophonIA/ELRC3.0 huggingface dataset:
English: In individuals at risk for renal disease more frequent monitoring of renal function is required.
Croatian: U osoba u s rizikom od bolesti bubrega potrebno je češće pratiti funkciju bubrega.
English: If you accidentally take more than the recommended dose of Emtricitabine/Tenofovir disoproxil Mylan, contact your doctor or nearest emergency department for advice.
Croatian: Ako slučajno uzmete veću dozu lijeka Emtricitabin/tenofovirdizoproksil Mylan od preporučene, obratite se svom liječniku ili najbližoj hitnoj službi.
English: Decreases in BMD of spine and changes in bone biomarkers from baseline were significantly greater in the tenofovir disoproxil treatment group at 144 weeks.
Croatian: Smanjenja BMD-a kralježnice i promjene koštanih biomarkera od početne vrijednosti bili su značajno veći u skupini liječenoj tenofovirdizoproksilom u 144. tjednu.
English: Animal studies on emtricitabine and tenofovir disoproxil do not indicate reproductive toxicity (see section 5.3).
Croatian: Ispitivanja emtricitabina i tenofovirdizoproksila na životinjama ne ukazuju na reproduktivnu toksičnost (vidjeti dio 5.3).
English: Emtricitabine triphosphate and tenofovir diphosphate competitively inhibit HIV-1 reverse transcriptase, resulting in DNA chain termination.
Croatian: Emtricitabintrifosfat i tenofovirdifosfat kompetitivno inhibiraju HIV-1 reverznu transkriptazu, što rezultira prekidom lanca DNK.
English: • Reminder on the risk of development of HIV-1 drug resistance in undiagnosed HIV-1-Infected individuals
Croatian: • podsjetnik o riziku od razvoja rezistencije virusa HIV 1 na lijekove u nedijagnosticiranih osoba zaraženih virusom HIV-1
English: Animal studies do not indicate harmful effects of emtricitabine or tenofovir disoproxil on fertility.
Croatian: Ispitivanja na životinjama ne ukazuju na štetan učinak emtricitabina ili tenofovirdizoproksila na plodnost.
English: There is close structural similarity between lamivudine and emtricitabine and similarities in the pharmacokinetics and pharmacodynamics of these two agents.
Croatian: Između lamivudina i emtricitabina postoji velika strukturna sličnost, kao i sličnosti u farmakokinetici i farmakodinamici tih dvaju lijekova.
English: Therefore, a careful benefit-risk assessment is needed when emtricitabine/tenofovir disoproxil is used in patients with creatinine clearance < 60 mL/min, and renal function should be closely monitored.
Croatian: Stoga je potrebna oprezna procjena odnosa koristi i rizika kad se emtricitabin/tenofovirdizoproksil primjenjuje u pacijenata s klirensom kreatinina < 60 ml/min i treba pažljivo pratiti funkciju bubrega.
English: Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).
Croatian: Autoimuni poremećaji (poput Gravesove bolesti i autoimunog hepatitisa) također su zabilježeni; međutim, prijavljeno vrijeme do nastupa poremećaja više varira i ti događaji mogu se pojaviti puno mjeseci nakon početka liječenja (vidjeti dio 4.4).
English: Emtricitabine and tenofovir pharmacokinetics are similar in male and female patients.
Croatian: Farmakokinetike emtricitabina i tenofovira slične su u pacijenata muškog i ženskog spola.
English: You may require blood tests for several months after stopping treatment.
Croatian: Možda ćete morati nekoliko mjeseci nakon prestanka liječenja raditi krvne pretrage.
English: However, tenofovir disoproxil reduced the viability index and weight of pups in a peri and postnatal toxicity study at maternally toxic doses.
Croatian: Ipak, tenofovirdizoproksil smanjio je indeks preživljenja i težinu mladunčadi u perinatalnom i postnatalnom ispitivanju toksičnosti pri dozama toksičnim za majku.
English: It is not known whether emtricitabine or tenofovir can be removed by peritoneal dialysis.
Croatian: Nije poznato mogu li se emtricitabin ili tenofovir ukloniti peritonejskom dijalizom.
English: • Take this medicine every day to reduce your risk, not just when you think you have been at risk of HIV infection.
Croatian: • Uzimajte ovaj lijek svaki dan kako biste smanjili rizik, a ne samo kad mislite da ste bili izloženi riziku od infekcije virusom HIV-a.
English: - this may cause the child to be tired or breathless.
Croatian: - mogu biti umorna i osjećati nedostatak zraka.
English: At week 48, six adolescents in the tenofovir disoproxil group and one adolescent in the placebo group had significant lumbar spine BMD loss (defined as > 4% loss).
Croatian: U 48. tjednu šest adolescenata u skupini koja je dobivala tenofovirdizoproksil i jedan adolescent u skupini koja je dobivala placebo imali su značajan gubitak BMD-a u području lumbalne kralježnice (definiran kao gubitak > 4%).
English: 8% (-1% to 17%)
Croatian: 8% (-1% do 17%)
English: Combination of emtricitabine and tenofovir disoproxil: Genotoxicity and repeated dose toxicity studies of one month or less with the combination of these two components found no exacerbation of toxicological effects compared to studies with the separate components.
Croatian: Kombinacija emtricitabina i tenofovirdizoproksila: Ispitivanja genotoksičnosti i toksičnosti ponovljenih doza u trajanju od jednog mjeseca ili manje s kombinacijom tih dvaju sastojaka nisu ustanovila egzacerbaciju toksikoloških učinaka u usporedbi s ispitivanjima provedenim sa svakom komponentom lijeka odvojeno.
English: Do not store above 25C.
Croatian: Ne čuvati na temperaturi iznad 25 C.
English: EU/1/16/1133/001 EU/1/16/1133/003 EU/1/16/1133/004 EU/1/16/1133/005 EU/1/16/1133/006
Croatian: EU/1/16/1133/003 EU/1/16/1133/004 EU/1/16/1133/005 EU/1/16/1133/006
English: This medicine is not a cure for HIV infection.
Croatian: Ovaj lijek neće izliječiti infekciju virusom HIV-a.
English: Neither emtricitabine nor tenofovir inhibited in vitro drug metabolism mediated by any of the major human CYP450 isoforms involved in drug biotransformation.
Croatian: Ni emtricitabin ni tenofovir in vitro nisu inhibirali metabolizam lijekova posredovan bilo kojim od glavnih humanih CYP450 izooblika uključenih u biotransformaciju lijekova.
English: Proximal renal tubulopathy generally resolved or improved after tenofovir disoproxil discontinuation.
Croatian: Proksimalna bubrežna tubulopatija općenito se povukla ili poboljšala nakon prekida terapije tenofovirdizoproksilom.
English: Pre-exposure prophylaxis in the paediatric population
Croatian: Predekspozicijska profilaksa u pedijatrijskoj populaciji
English: Emtricitabine is a nucleoside reverse transcriptase inhibitor and tenofovir is a nucleotide reverse transcriptase inhibitor.
Croatian: Emtricitabin je nukleozidni inhibitor reverzne transkriptaze, a tenofovir je nukleotidni inhibitor reverzne transkriptaze.
English: Female
Croatian: Ženski
English: 1 Data generated from simultaneous dosing with ledipasvir/sofosbuvir.
Croatian: 1 Podaci generirani prilikom istovremene primjene s ledipasvirom/sofosbuvirom.
English: In addition to the adverse reactions reported in adults, anaemia (9.5%) and skin discolouration (31.8%) occurred more frequently in clinical trials in paediatric patients than in adults (see section 4.8, Tabulated summary of adverse reactions).
Croatian: Uz nuspojave zabilježene u odraslih, anemija (9,5%) i promjena boje kože (31,8%) pojavile su se češće u kliničkim ispitivanjima u pedijatrijskih pacijenata nego u odraslih (vidjeti dio 4.8, Tablični prikaz nuspojava).
English: Limited data from clinical studies support once daily dosing in HIV-1 uninfected individuals with CrCl 60-80 mL/min.
Croatian: Ograničeni podaci iz kliničkih ispitivanja govore u prilog doziranju jedanput na dan u osoba koje nisu zaražene virusom HIV-1 i imaju CrCl 60 - 80 ml/min.
English: angioedema3
Croatian: angioedem3
English: BGP Products ApS Tel: + 4528116932 (Danmörk)
Croatian: BGP Products ApSTel: + 4528116932 (Danmörk)
English: b Relative risk reduction calculated for mITT based on incident seroconversion, ie, occurring post-baseline through first posttreatment visit (approximately 1 month after last study drug dispensation).
Croatian: b Smanjenje relativnog rizika izračunato za mITT na temelju incidentne serokonverzije, tj. one koja je nastupila u razdoblju nakon početka ispitivanja do prve kontrole nakon početka liječenja (približno 1 mjesec nakon zadnjeg izdavanja ispitivanog lijeka).
English: Renal and bone effects in the paediatric population
Croatian: Učinci na bubrege i kosti u pedijatrijskoj populaciji
English: At baseline the randomised groups had similar median plasma HIV-1 RNA (5.02 and 5.00 log10 copies/mL) and CD4 counts (233 and 241 cells/mm3).
Croatian: Na početku su randomizirane skupine imale sličan medijan plazmatske HIV-1 RNK (5,02 i 5,00 log10 kopija/ml) i broj CD4 stanica (233 i 241 stanica/mm3).
English: In vitro studies have shown that both emtricitabine and tenofovir can be fully phosphorylated when combined together in cells.
Croatian: Ispitivanja in vitro pokazala su da se i emtricitabin i tenofovir mogu potpuno fosforilirati kada se zajedno kombiniraju u stanicama.
English: Dose interval adjustments are recommended for HIV-1 infected patients with creatinine clearance 30-49 mL/min (see section 4.2).
Croatian: Preporučuje se prilagođavanje intervala doziranja kod pacijenata zaraženih virusom HIV-1 s klirensom kreatinina između 30−49 ml/min (vidjeti dio 4.2).
English: The 48-week primary endpoint data showed that the combination of emtricitabine, tenofovir disoproxil and efavirenz provided superior antiviral efficacy as compared with the fixed combination of lamivudine and zidovudine with efavirenz as shown in Table 4.
Croatian: Podaci primarne mjere ishoda nakon 48 tjedana pokazali su da je kombinacija emtricitabina, tenofovirdizoproksila i efavirenza imala veću antivirusnu djelotvornost u usporedbi s fiksnom kombinacijom lamivudina i zidovudina s efavirenzom, kako je pokazano u Tablici
English: Genotoxicity studies revealed positive results in the in vitro mouse lymphoma assay, equivocal results in one of the strains used in the Ames test, and weakly positive results in an UDS test in primary rat hepatocytes.
Croatian: Ispitivanja genotoksičnosti dala su pozitivne rezultate u in vitro testu mišjeg limfoma, nepouzdane rezultate u jednom soju upotrijebljenom u Amesovom testu i slabo pozitivne rezultate UDS testa (UDS, unscheduled DNA synthesis; test neplanirane DNK sinteze) na primarnim hepatocitima štakora.
English: This medicine can only help reduce your risk of getting HIV before you are infected.
Croatian: Ovaj lijek Vam može pomoći da smanjite rizik od dobivanja HIV-a samo prije zaraze.
English: Administration of emtricitabine/tenofovir disoproxil with food resulted in a delay of approximately three quarters of an hour in reaching maximum tenofovir concentrations and increases in tenofovir AUC and Cmax of approximately 35% and 15%, respectively, when administered with a high fat or light meal, compared to administration in the fasted state.
Croatian: Uzimanje emtricitabin/tenofovirdizoproksila s hranom rezultiralo je odgodom od približno tri četvrtine sata u postizanju maksimalnih koncentracija tenofovira i porastom vrijednosti AUC i Cmax za tenofovir od približno 35% odnosno 15%, kada je lijek uziman s obrokom bogatim mastima ili s laganim obrokom, u usporedbi s uzimanjem natašte.
English: Use of tenofovir disoproxil may cause a reduction in BMD.
Croatian: Primjena tenofovirdizoproksila može izazvati smanjenje BMD-a.
English: The systemic clearance of emtricitabine averaged 307 mL/min.
Croatian: Sistemski klirens emtricitabina u prosjeku je iznosio 307 ml/min.
English: Table 2: Interactions between emtricitabine/tenofovir disoproxil or its individual component(s) and other medicinal products
Croatian: Tablica 2: Interakcije između emtricitabin/tenofovirdizoproksila ili njegovih pojedinačnih komponenti i drugih lijekova
English: These may be signs of HIV infection:
Croatian: Ovo mogu biti znakovi infekcije virusom HIV-a:
English: In addition, the clinical response to treatment should be closely monitored in patients receiving emtricitabine/tenofovir disoproxil at a prolonged dosing interval.
Croatian: Osim toga, klinički odgovor na liječenje treba pažljivo pratiti u pacijenata koji primaju emtricitabin/tenofovirdizoproksil u produljenom intervalu doziranja.
English: Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment.
Croatian: Autoimuni poremećaji (poput Gravesove bolesti i autoimunog hepatitisa) također su zabilježeni u okruženju imunološke reaktivacije; međutim, prijavljeno vrijeme do nastupa poremećaja više varira i ti događaji mogu se pojaviti puno mjeseci nakon početka liječenja.
English: Some patients taking combination antiretroviral medicines such as emtricitabine/tenofovir disoproxil may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone).
Croatian: U nekih se pacijenata koji uzimaju kombiniranu antiretrovirusnu terapiju kao što je emtricitabin/tenofovirdizoproksil može razviti koštana bolest koja se naziva osteonekrozom (odumiranje koštanog tkiva uzrokovano gubitkom opskrbe kosti krvlju).
English: Baseline characteristics are summarised in Table 8.
Croatian: Početne značajke sažeto su prikazane u Tablici 8.
English: • That a multidisciplinary approach is recommended for the management of paediatric patients
Croatian: • U liječenju pedijatrijskih pacijenata preporučuje se multidisciplinarni pristup.
English: Steady-state pharmacokinetics of tenofovir were evaluated in 8 HIV-1 infected adolescent patients (aged 12 to < 18 years) with body weight ≥ 35 kg and in 23 HIV-1 infected children aged 2 to < 12 years.
Croatian: Farmakokinetika tenofovira u stanju dinamičke ravnoteže bila je procijenjena u 8 adolescentnih pacijenata zaraženih virusom HIV-1 (u dobi od 12 do < 18 godina) tjelesne težine ≥ 35 kg i u 23 djece zaražene virusom HIV-1 u dobi od 2 do < 12 godina.
English: Baseline characteristics are summarised in Table 5.
Croatian: Početne značajke sažeto su prikazane u Tablici 5.
English: Emtricitabine-resistant viruses with the M184V/I mutation were cross-resistant to lamivudine, but retained sensitivity to didanosine, stavudine, tenofovir and zidovudine.
Croatian: Virusi rezistentni na emtricitabin s mutacijom M184V/I bili su križno rezistentni na lamivudin, ali su zadržali osjetljivost na didanozin, stavudin, tenofovir i zidovudin.
English: elevated amylase including elevated pancreatic amylase, elevated serum lipase, vomiting, abdominal pain, dyspepsia abdominal pain, abdominal distension, flatulence
Croatian: povišena amilaza uključujući povišenu amilazu gušterače, povišena serumska lipaza, povraćanje, bolovi u trbuhu, dispepsija bolovi u trbuhu, distenzija trbuha, flatulencija
English: Risk of resistance with undetected HIV-1 infection:
Croatian: Rizik od rezistencije kod neotkrivene infekcije virusom HIV-1:
English: HIV-1 infected patients receiving emtricitabine/tenofovir disoproxil or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV infection, and therefore should remain under close clinical observation by physicians experienced in the treatment of patients with HIV associated diseases.
Croatian: Pacijenti zaraženi virusom HIV-1 koji primaju emtricitabin/tenofovirdizoproksil ili neku drugu antiretrovirusnu terapiju mogu i dalje razvijati oportunističke infekcije i druge komplikacije infekcije HIV-om pa stoga trebaju biti pod pažljivim kliničkim nadzorom liječnika s iskustvom u liječenju pacijenata s bolestima povezanima s HIV-om.
English: Emtricitabine and tenofovir are primarily excreted by the kidneys by a combination of glomerular filtration and active tubular secretion.
Croatian: Emtricitabin i tenofovir primarno se izlučuju putem bubrega kombinacijom glomerularne filtracije i aktivne tubularne sekrecije.
English: Emtricitabine/tenofovir disoproxil has not been studied in HIV-1 uninfected individuals with creatinine clearance < 60 mL/min and is therefore not recommended for use in this population.
Croatian: Emtricitabin/tenofovirdizoproksil nije ispitan u osoba koje nisu zaražene virusom HIV-1 s klirensom kreatinina < 60 ml/min, pa se stoga ne preporučuje njegova primjena u toj populaciji.
English: There have been reports of a high rate of virological failure and of emergence of resistance at an early stage in HIV-1 infected patients when tenofovir disoproxil was combined with lamivudine and abacavir as well as with lamivudine and didanosine as a once daily regimen.
Croatian: Postoje izvješća o visokoj stopi virološkog neuspjeha i pojavi rezistencije u početnom stadiju kod pacijenata zaraženih virusom HIV-1 kada se tenofovirdizoproksil kombinirao s lamivudinom i abakavirom, kao i s lamivudinom i didanozinom u režimu liječenja jedanput na dan.
English: Rarely, inflammation of the pancreas and lactic acidosis (excess lactic acid in the blood), which sometimes causes death, have been reported when medicines containing tenofovir disoproxil and didanosine were taken together.
Croatian: U rijetkim su slučajevima zabilježene upala gušterače i laktacidoza (prekomjerna količina mliječne kiseline u krvi), koje katkada uzrokuju smrt, kada su se zajedno uzimali lijekovi koji sadržavaju tenofovirdizoproksil i didanozin.
English: Patients with HIV-1 harbouring mutations
Croatian: Pacijenti s virusom HIV-1 koji nosi mutaciju
English: Liver disease
Croatian: Bolest jetre
English: neutropenia
Croatian: neutropenija
English: In vitro binding of emtricitabine to human plasma proteins was < 4% and independent of concentration over the range of 0.02
Croatian: In vitro vezanje emtricitabina na humane plazmatske proteine bilo je < 4% i nije ovisilo o koncentraciji u rasponu od 0,02 do 200 µg/ml.
English: • If you are an adult taking this medicine to reduce the risk of getting HIV, take this medicine every day, not just when you think you have been at risk of HIV infection.
Croatian: • Ako ste odrasla osoba i uzimate ovaj lijek radi smanjenja rizika od dobivanja HIV-a, uzimajte ga svaki dan, ne samo kada mislite da ste bili izloženi riziku od infekcije virusom HIVa.
English: The marketing authorisation holder (MAH) shall ensure that all physicians who are expected to prescribe/use Emtricitabine/Tenofovir disoproxil Mylan in either adolescent patients for the treatment of HIV-1 infection or in adults and adolescents for PrEP are provided with a physician educational pack containing the Summary of Product Characteristics and an appropriate educational brochure, as detailed below:
Croatian: Nositelj odobrenja za stavljanje lijeka u promet osigurat će da svi liječnici za koje se očekuje da će propisivati/primjenjivati Emtricitabin/tenofovirdizoproksil Mylan, bilo adolescentnim bolesnicima za liječenje infekcije virusom HIV-1, bilo odraslim osobama i adolescentima za predekspozicijsku profilaksu, dobiju edukacijski paket za liječnike koji sadrži sažetak opisa svojstava lijeka i odgovarajuće edukacijske brošure, kako je detaljno opisano niže:
English: However, in some HIV-1 infected patients, declines in creatinine clearance did not completely resolve despite tenofovir disoproxil discontinuation.
Croatian: Međutim, u nekih se pacijenata zaraženih virusom HIV-1 smanjenje klirensa kreatinina nije potpuno povuklo usprkos prekidu terapije tenofovirdizoproksilom.
English: No data are available to make dose recommendations (see sections 4.2 and 4.4).
Croatian: Nema dostupnih podataka na temelju kojih bi se mogla preporučiti doza (vidjeti dijelove 4.2 i 4.4).
English: • increased creatinine in your blood
Croatian: • povišenu razinu kreatinina u krvi
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON OF MULTIPACK (WITH BLUE BOX)
Croatian: PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU VANJSKA KUTIJA VIŠESTRUKOG PAKIRANJA (S PLAVIM OKVIROM)
English: • Genotypic resistance to efavirenz, predominantly the K103N mutation, developed in virus from 13/19 (68%) patients in the emtricitabine/tenofovir disoproxil/efavirenz group and in virus from 21/29 (72%) patients in the comparative group.
Croatian: • Genotipska rezistencija na efavirenz, pretežno mutacija K103N, razvila se kod virusa u 13/19 (68%) pacijenata iz skupine emtricitabin/tenofovirdizoproksil/efavirenz te kod virusa u 21/29 (72%) pacijenata u usporednoj skupini.
English: a Relative risk reduction calculated for mITT cohort based on incident (post-baseline) seroconversion.
Croatian: a Smanjenje relativnog rizika izračunato za mITT kohortu na temelju incidentne serokonverzije (nakon početka ispitivanja).
English: Emtricitabine/tenofovir disoproxil should only be used for pre-exposure prophylaxis as part of an overall HIV-1 infection prevention strategy including the use of other HIV-1 prevention measures (e.g. consistent and correct condom use, knowledge of HIV-1 status, regular testing for other sexually transmitted infections).
Croatian: Emtricitabin/tenofovirdizoproksil smije se primjenjivati za predekspozicijsku profilaksu samo u sklopu ukupne strategije sprječavanja infekcije virusom HIV-1, koja uključuje i primjenu drugih mjera sprječavanja infekcije virusom HIV-1 (npr. dosljedna i ispravna uporaba kondoma, poznavanje HIV-1 statusa, redovito testiranje na druge spolno prenosive infekcije).
English: However, both are generally known as NRTIs and they work by interfering with the normal working of an enzyme (reverse transcriptase) that is essential for the virus to reproduce itself.
Croatian: NRTIs), a djeluju tako da ometaju normalan rad enzima (reverzne transkriptaze) koji je ključan za reprodukciju virusa.
English: In some patients with advanced liver disease or cirrhosis, stopping treatment is not recommended as this may lead to worsening of your hepatitis, which may be life-threatening.
Croatian: U nekih se pacijenata s uznapredovalom bolešću jetre ili cirozom jetre ne preporučuje prekid liječenja, jer to može dovesti do pogoršanja hepatitisa, koje može biti životno ugrožavajuće.
English: Seven patients had estimated glomerular filtration rate (GFR) values between 70 and 90 mL/min/1.73 m2.
Croatian: Sedmero pacijenata imalo je procijenjenu brzinu glomerularne filtracije između 70 i 90 ml/min/1,73 m².
English: The mean changes in CD4 cell count from baseline were +185 cells/mm3 and +196 cells/mm3 respectively.
Croatian: Srednje promjene broja CD4 stanica od početne vrijednosti bile su +185 stanica/mm3 odnosno +196 stanica/mm3.
English: Patients at risk of renal impairment (such as patients with baseline renal risk factors, advanced HIV disease, or patients receiving concomitant nephrotoxic medications) are at increased risk of experiencing incomplete recovery of renal function despite tenofovir disoproxil discontinuation (see section 4.4).
Croatian: Pacijenti s rizikom od oštećenja funkcije bubrega (kao što su pacijenti s početnim bubrežnim čimbenicima rizika, uznapredovalom HIV bolešću ili pacijenti koji istovremeno primaju nefrotoksične lijekove) pod povećanim su rizikom od nepotpunog oporavka funkcije bubrega usprkos prekidu terapije tenofovirdizoproksilom (vidjeti dio 4.4).
English: For monitoring of blood lipids and glucose reference is made to established HIV treatment guidelines.
Croatian: Za praćenje lipida i glukoze u krvi date su preporuke u uspostavljenim smjernicama za liječenje HIV-a.
English: The K65R mutation can also be selected by abacavir or didanosine and results in reduced susceptibility to these agents plus lamivudine, emtricitabine and tenofovir.
Croatian: Mutacija K65R može se također izdvojiti s abakavirom ili didanozinom, a rezultira smanjenom osjetljivošću na ove lijekove plus lamivudin, emtricitabin i tenofovir.
English: While taking Emtricitabine/Tenofovir disoproxil Mylan you may still develop infections or other illnesses associated with HIV infection.
Croatian: Dok uzimate lijek Emtricitabin/tenofovirdizoproksil Mylan i dalje možete razviti infekcije ili druge bolesti povezane s infekcijom virusom HIV-a.